| P2093 | author name string | Baohui Han | |
| | Jie Shen | |
| | Chunlei Shi | |
| | Aiqin Gu | |
| | Liwen Xiong | |
| P2860 | cites work | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
| | Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 |
| | Erlotinib in previously treated non-small-cell lung cancer | Q29547546 |
| | Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 |
| | Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. | Q30650378 |
| | TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 |
| | Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer | Q35017984 |
| | Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. | Q35610264 |
| | Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs | Q36692592 |
| | Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer | Q37756959 |
| | Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 |
| | Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study | Q42673292 |
| | Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. | Q43056663 |
| | Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). | Q50782266 |
| | Epidemiology of Lung Cancer* | Q54195851 |
| | Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time | Q81219117 |
| P433 | issue | 6 | |
| P407 | language of work or name | Chinese | Q7850 |
| P921 | main subject | adenocarcinoma | Q356033 |
| | erlotinib | Q418369 |
| P304 | page(s) | 529-533 | |
| P577 | publication date | 2011-06-01 | |
| P1433 | published in | Chinese Journal of Lung Cancer | Q26842043 |
| P1476 | title | [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. | |
| P478 | volume | 14 | |